Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
IMInsight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX)

NASDAQ Capital Market · Currency in USD
$2.83 ▼ -0.01 (-0.35%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.83 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$2.84
Open
$2.92
Day's Range
$2.78 – $2.92
52 Week Range
$2.42 – $8.51
Volume
42,479
Avg. Volume
237,882
Market Cap
$92.61M
Beta (5Y Monthly)
1.81
PE Ratio (TTM)
--
EPS (TTM)
-$1.34
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.75

Profile: Insight Molecular Diagnostics Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
57
CEO
Joshua Riggs

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.24 · Revenue est. $235.12K
DateEst.Actual
Aug 10, 2026-$0.25-$0.31Miss
May 13, 2026-$0.26-$0.12Beat
Mar 26, 2026-$0.24-$0.72Miss
Nov 10, 2025-$0.21-$0.34Miss
Aug 14, 2025-$0.23-$0.30Miss
May 12, 2025-$0.24-$0.26Miss

Analyst view

Consensus price target
$9.75 ▲ +244.5%
Range $8.00 – $12.00
Rating: Buy
Buy 64% · Hold 36% · Sell 0%

Get free alerts on IMDX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.